Análisis del polimorfismo CYP2C19*2 en la población castellanoleonesa

Abstract

Cytochrome CYP P450 enzymes carry out 75% of biotransformation reactions of drugs, so their polymorphisms have great pharmacokinetic relevance. The polymorphisms of the CYP2C19 gene affect the metabolism of antiulcer drugs, proton pump inhibitors. Specifically, the g.19154G>A polymorphism gives rise to a null enzyme, which results in poor metabolic activity. This polymorphism affects a recognition site for the restriction enzyme Sma I, so its detection can be carried out by simple molecular biology techniques. Interestingly, the presence of the polymorphism results in a greater efficacy of the Helicobacter pylori eradication treatment. In this work we have analyzed the incidence of this polymorphism in a sample of 208 people from the Autonomous Community of Castilla y León, with emphasis on the population of Salamanca. The global proportions of heterozygotes and homozygotes for the polymorphism are in agreement with the literature. However, we have found a lower percentage of polymorphic alleles among individuals born in Salamanca, compared to other provinces. It would be interesting to increase the sample for this population and study the correlation of this polymorphism with the high incidence of gastric cancer in the Community.